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Introduction: Recent studies suggested that p95HER2, the NH2-
terminally truncated form of human epidermal growth factor recep-
tor 2 (HER2), could confer resistance to monoclonal antibodies
against HER2 (HER2-mab). The aim of this study was to investigate
the role of p95HER2 according to HER2 gene copy number (GCN)
and HER2 mutation in non-small cell lung cancer (NSCLC).
Methods: The study included 447 resected NSCLC patients evalu-
ated for P95HER2 status by immunofluorescence. Data were corre-
lated with HER2 GCN evaluated by fluorescence in situ hybridiza-
tion (FISH) and HER2 mutations. Tumors were scored as positive
for p95HER2 expression if any cytoplasmic staining was detected.
Results: P95HER2 was successfully evaluated in 431 patients and
was positive (p95HER2) in 33 (7.6%) cases. HER2 GCN was
evaluable in 439 patients, and increased GCN (at least four copies in
at least 40% cells) was found in 60 cases, of which 22 (5.0%)
displayed gene amplification (GA). Among the 22 patients with
HER2 amplification, only one resulted P95HER2. To further
investigate whether the receptor is truncated in presence of gene
mutation, in addition to the study cohort, we analyzed p95HER2
status in eight NSCLC samples harboring HER2 mutation, and only
one case resulted p95HER2. In the whole population, p95HER2
patients had numerically higher risk of death than p95HER2
(hazard ratio  1.4, p  0.2). No difference in survival was
observed between patients with or without HER2 GA (median 38
versus 41 months, p 0.46). HER2 GA was significantly associated
with EGFR and MET GA, with no effect on survival.
Conclusions: HER2 truncation and HER2 increased GCN are not
prognostic in resected NSCLC. P95HER2 is a very rare event in
individuals displaying HER2 gene amplification or mutation.
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Non-small cell lung cancer (NSCLC) remains the leadingcause of cancer-related deaths worldwide, and in 2011 it
is estimated that it will be responsible for more deaths than
colorectal cancer, breast cancer, and prostate cancer com-
bined.1 For patients with advanced disease, chemotherapy
with third-generation platinum-based doublets represented
the standard of care until recently, when major breakthroughs
in the knowledge of cancer biology permitted the develop-
ment of numerous targeted therapies for NSCLC treatment.
The epidermal growth factor receptor (EGFR) is a prototyp-
ical member of the EGFR family that also includes HER2/neu
(Erb-B2), HER3 (Erb-B3), and HER4 (Erb-B4).2 These re-
ceptors represent interesting therapeutic targets because they
play a critical role in cancer proliferation and survival.
Anti-EGFR agents and particularly small molecules
interfering with the tyrosine kinase activity of the intracellu-
lar domain of EGFR represent today an important option
against NSCLC, particularly in individuals harboring activat-
ing EGFR mutations.3 HER2 has strong kinase activity but
has no identified ligand. HER2 overexpression or amplifica-
tion correlates with poor prognosis in several malignancies
including breast and ovarian cancers.4,5 Nevertheless, in lung
cancer, the role of HER2 overexpression and amplification,
reported in 20% and 10% of cases, respectively,6 remains
controversial. A recent meta-analysis showed that HER2
overexpression but not amplification was a poor prognostic
factor in lung cancer, particularly in small cell lung cancer, in
adenocarcinoma, and in early-stage NSCLC.7
Anti-HER2 strategies, and particularly the monoclonal
antibody trastuzumab, are effective for HER2 overexpression
or amplified breast and gastric cancers when used in combi-
nation with cytotoxic agents.8,9 By contrast, clinical trials
using anti-HER2 monoclonal antibodies (HER2-mab) in
NSCLC patients have reported modest or disappointing re-
sults.10–15 In a phase II study, Herbst et al.11 evaluated the
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efficacy of single-agent pertuzumab, a monoclonal antibody
that binds HER2’s dimerization domain and inhibits HER2
signaling. Among the 43 enrolled patients, no responses were
seen, indicating lack of efficacy of the drug at least as single
agent in unselected population. Nevertheless, preclinical data
and anecdotic clinical data showed that HER2-mab or ty-
rosine kinase inhibitors could be effective in presence of
HER2 gene mutations.16,17
Amino terminally truncated carboxyl terminal fragments
of HER2, collectively known as p95HER2, are frequently found
in HER2-expressing breast cancer cell lines and tumors.18 The
biologic function of p95HER2 has not been fully character-
ized, although overexpression of p95HER2 has been shown
to lead to growth of tumor xenografts in nude mice.19 In
breast cancer, p95HER2 is present in approximately 11% of
HER2 overexpressing tumors and it is responsible for trastu-
zumab resistance.20
Based on these data we hypothesized that, despite the
fact that 5% of NSCLC display HER2 gene amplification,
the lack of efficacy of HER2-mab could be largely related to
p95HER2 truncation. The aim of this study was to assess
whether p95HER2 truncation is an event occurring in
NSCLC and how such event was associated with HER2 gene
copy number (GCN) and presence of HER2 mutations.
PATIENT CHARACTERISTICS AND METHODS
Cohort
This study was conducted in a cohort of 447 NSCLC
patients previously analyzed for MET (mesenchymal-epithe-
lial transition factor) GCN by fluorescence in situ hybridiza-
tion (FISH).21 As previously described (Table 1), the majority
of patients were male (83.4%), former (51.9%) or current
(35.1%) smokers, with moderately or poorly differentiated
tumors (grade II and III); the median age was 66 years; all
patients received radical surgery, with evidence of patholog-
ical stage III in 34.7% and stage IV in 6% of cases; and a total
of 161 patients were EGFR FISH positive and 48 patients
were considered as MET FISH positive according to the
previously described criteria.21,22 No postoperative therapy
was delivered to patients in stage I–II, and only a minority of
patients with stage III disease (18 cases) received adjuvant
platinum-based chemotherapy. Patients with stage III disease
and pathological evidence of N2 disease (n  101) received
postoperative mediastinal radiotherapy. With a median fol-
low-up of 40 months, in the whole population, overall sur-
vival was 43.9 months. The criteria used for patient selection
included availability of tumor tissue from primary lung can-
cer and survival data. The study was approved by the local
Ethics Committee and was conducted in accordance with
ethical principles stated in the most recent version of the
Declaration of Helsinki or the applicable guidelines on good
clinical practice, whichever represented the greater protection
of the individuals.
Tissue Microarray
Paraffin-embedded tumor specimens were used to con-
struct a tissue microarray (TMA) with 600 m diameter
cores. Three tissue cores represented each patient. An adhe-
sive-coated tape system (Instrumedics, Hackensack, NJ) was
used for sectioning the tumor array blocks at 4 m.
p95HER2 Immunofluorescence and HER2
Immunohistochemistry
Immunohistochemistry (IHC) was performed on 3 m
tissue sections from the TMA blocks. Immunoreaction was
displayed using the avidin-biotin-peroxidase complex
method. Peroxidase activity was visualized with diaminoben-
zidine. Counterstaining was performed with hematoxylin.
The negative controls were carried out by omitting the pri-
mary antibodies. Immunostaining was done using a Bench-
mark immunostainer (Ventana Medical System, Inc., Tucson,
AZ). In all cases, the immunohistochemical evaluation was
performed independently by two pathologists (G.A. and G.F.)
who were blind to the clinicopathological characteristics and
treatment of the patients. In all the discordant cases, a mutual
agreement was eventually reached. Sections were incubated
with HER2/neu antibody (ready to use for the Ventana
automated slide stainer) according to the protocol of the
manufacture (Ventana Medical System, Inc). Each slide was
evaluated and scored on a 0 to 3 scale, following uniform
TABLE 1. Patient Characteristics
Characteristics Total %
Total 447
Median age, yr (range) 66 (33–86)
Gender
Male 373 83.4
Female 74 16.6
Smoking history
Never 40 8.9
Former 232 51.9
Current 157 35.1
Unknown 18 4.1
Histology
Adenocarcinoma  BAC 241 53.9
Squamous cell carcinoma 139 31.1
Othera 67 15.0
Pathological stage
I 166 37.1
II 99 22.2
IIIb 155 34.7
IV 27 6.0
Grade
I 32 7.2
II 255 57.3
III 158 35.2
Not defined 2 0.3
EGFR FISH 161 42.8c
MET FISH 48 11.1d
a Other histology included 7 patients with large cell carcinoma, 28 with neuroen-
docrine differentiation and undifferentiated NSCLC.
b Stage III included 101 cases in stage IIIA and 54 cases in stage IIIB.
c EGFR FISH analysis was performed in 376 cases.
d MET FISH analysis was performed in 435 cases.
EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization;
MET, mesenchymal-epithelial transition factor; BAC, bronchioloalveolar carcinoma.
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guidelines developed for breast cancer testing.23 No staining
was 0, 1 indicated faint partial membrane staining in more
than 10% of the tumor cells, 2 indicated weak to moderate
complete membrane staining in more than 10% of the tumor
cells, and 3 indicated moderate to strong complete mem-
brane staining in more than 10% of the tumor cells.
The expression of NH2-terminally truncated form of
HER2 (p95Her2) was evaluated by immunofluorescence as
previously described.20,24 Analysis was performed on two
sequential 3-m tissue sections from the TMA blocks. After
deparaffinization, the slides were incubated in 10 mM citrate
buffer (pH 6.0) in a heated (95–99°C) water bath for 40
minutes for antigen retrieval. After rinse with dH2O and
phosphate buffered saline (PBS), the sections were immersed
in a PBS/4% BSA solution for 10 minutes to block nonspe-
cific binding. Then, one section of all tumors was incubated
at room temperature with a mouse monoclonal antibody to
the intracellular domain of HER2 (clone CB11, Biogenex,
San Ramon, CA) diluted 1:20 for 60 minutes, and another
sequential section of all tumors was incubated with a mouse
monoclonal antibody to the extracellular domain of HER2
(clone CBE1, Novocastra, UK) diluted 1:10 for 120 minutes.
Both sections were then incubated with a rabbit polyclonal
cytoplasmic anticytokeratin (Pan) (Invitrogen, Carlsbad, CA)
diluted 1:50 for 30 minutes. After rinse with PBS, the
sections were incubated with Alexa Fluor 555 antimouse IgG
(Cell Signaling Technology, Beverly, MA) diluted 1:500 for
30 minutes to detect HER2 antibodies and with Alexa Fluor
488 antirabbit IgG diluted 1:500 for 30 minutes to detect
cytokeratin antibody (Cell Signaling Technology). Then sec-
tions were counterstained with 4,6-diamidino-2-phenyl-
indole dihydrochloride (Abbot Molecular Inc., Des Plaines,
IL). If any cytoplasmic staining was detected with CB11
anti-HER2 antibody, tumors were scored as positive for
p95HER2 expression.20 Cytoplasmic staining was confirming
both with the colocalization of CB11 anti-HER2 antibody
with the anticytokeratin antibody that showed yellow signal
(red and green overlapping) and with the comparison with the
pure membrane staining observed with the CBE1 anti-
HER2 antibody. Staining was evaluated using Olympus
BX-61 fluorescence microscope (Olympus America, Cen-
ter Valley, PA) by two pathologists (G.A. and G.F.) who
were blind to the clinicopathological characteristics and
treatment of the patients.
HER2 FISH
Unstained 4-m sections from each of the three TMA
were submitted to dual-target, dual-color FISH assays using
the PathVysion HER-2 DNA probe Kit (Vysis/Abbott Labo-
ratories), which includes the LSI HER-2 SpectrumOrange
and the CEP 17 SpectrumGreen probes. The FISH assays
were performed according to protocol previously de-
scribed,6,22 including pretreatment with 2SSC at 75°C and
digestion with Proteinase K for 7 to 15 minutes each, code-
naturation at 85°C for 15 minutes, hybridization for approx-
imately 36 hours, and rapid posthybridization washes with
2SCC/0.4 NP40. Signals were enumerated in 30 tumor
nuclei per core, using epifluorescence microscope with single
interference filter sets for green (FITC), red (Texas red), and
blue (DAPI) as well as dual (red/green) and triple (blue, red,
green) band pass filters. Analysis was performed indepen-
dently by two observers (Y.G.C. and M.V.G.) blinded to the
patients’ clinical characteristics. Results were analyzed ac-
cording to FISH criteria previously reported.25 When heter-
ogeneous results were detected among the three tested cores,
the core with the highest result was used to represent the
patient in the statistic analyses. For documentation, images
were captured using a charge-coupled device camera and
merged using dedicated software (CytoVision, AI, Santa
Clara, CA).
HER2 Mutation Analysis
Genomic DNA was extracted from tumors and normal
lung tissues according to standard procedures. Genetic anal-
ysis of the HER2 gene was performed by polymerase chain
reaction amplification of exons 19 and 20 with flanking
intronic sequences followed by high-resolution melting anal-
ysis and sequencing. The primers for polymerase chain reac-
tion amplification were previously reported.26 Tumor DNA
samples found to be positive by high-resolution melting
analysis were reamplified in duplicates, using the same ex-
perimental conditions, purified, and subjected to bidirectional
dye-terminator sequencing with the same primers employed
for amplification. Sequencing fragments were detected by
capillary electrophoresis using the ABI Prism 3100 DNA
analyzer (Applied Biosystems). Sequence chromatograms
were analyzed by Mutation Surveyor 2.61 (SoftGenetics,
State College, PA) followed by manual review.
Statistical Analyses
Kaplan-Meier analyses were performed to compare
survival curves of subgroups of patients in different condi-
tions.27 A log-rank test was used to test differences between
survival and progression curves. Linear univariate and mul-
tivariate regression models were used to select relevant vari-
ables, and some statistics of each model were calculated such
as odds ratio and relative risk with their respective confidence
intervals. Levels of the response in the regression model were
converted to a dichotomous variable where necessary. All the
analyses were performed on Matlab (The MathWorks, Inc.,
Natick, MA) in house-built routines.
RESULTS
p95HER2
A total of 431 cases were fully evaluated for HER2
expression by IHC and for p95HER2 by immunofluores-
cence. HER2 overexpression (HER2 IHC positive) was found
in 141 cases (32.7%) including 33 patients (7.7%) expressing
p95HER2 (Figure 1). In the whole population, HER2 IHC
positive status was not associated with patient survival (data
not shown). As illustrated in Table 2, p95HER2 status was
not associated with any clinical or biological characteristic
except for histology. Among the 33 p95HER2 cases, 26
(78.7%) had a nonadenocarcinoma histology (p  0.001).
Interestingly, presence of p95HER2 was detected in only one
patient with HER2 gene amplification. To further investigate
whether the receptor is truncated in presence of gene muta-
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tion, in addition to the study cohort, we analyzed p95HER2
status in eight NSCLC samples harboring HER2 mutation. In
this small cohort of gene mutant NSCLC, one case resulted
p95HER2. As shown in Figure 2, in the whole population,
p95HER2 patients had a shorter survival than p95HER2
(41.3 months versus not reached, p  0.21; hazard ratio: 1.41,
95% confidence interval: 1.08–1.82) even if the difference was
not statistically significant. No difference in survival was ob-
served in any subgroup of patients, as illustrated in Table 3.
HER2 FISH
Among the 447 patients included in the study, 439 were
successfully analyzed by FISH. Using the scoring system
adopted in previous studies,6,22,25 HER2 FISH positive status
(4 HER2 copies in 40% of cells) was found in 60 cases
(17.6%), including 22 cases (5.0%) with gene amplification,
defined according to breast cancer criteria.23 As illustrated in
Table 4, HER2 FISH positive status was more frequently
observed in patients with adenocarcinoma histology, even if
the association was not statistically significant (0.09). No
association with any other clinical characteristic was ob-
served. As previously reported by our group,6 HER2 FISH
positive status was significantly associated with increased
EGFR (p  0.00004) and MET (p  0.005) GCN. Interest-
ingly, among the 22 patients with HER2 gene amplification,
15 (68.1%) resulted coamplified for MET gene and 4
FIGURE 1. p95HER2 immunofluorescence. Immunofluorescence assay for detection of p95HER2 (top  p95HER2 negative
case, bottom  p95HER2 case). HER2 intracellular domain staining (red) colocalizes with cytokeratin staining (green) only in
p95HER2 tumors. Colocalization appears as a yellow (red and green merged) signal.
TABLE 2. p95HER2 and Association with Clinical and
Biological Characteristics
Characteristic
p95HER2,
N (%)
p95HER2,
N (%) p
All 33 (7.7) 398 (92.3)
Female 2 (2.9) 68 (97.1) 0.12
Male 31 (8.6) 330 (91.4)
Never-smokers 0 (0) 40 (100) 0.09
Smokers (former  current) 33 (8.9) 341 (91.1)
Adenocarcinoma 7 (3.2) 210 (96.8) 0.001
Other histology 26 (12.1) 188 (87.9)
Grade I–II 19 (7.1) 249 (92.9) 0.68
Grade III 12 (8.2) 134 (91.8)
Stage I–II 24 (9.2) 237 (90.8) 0.26
Stage III–IV 9 (6.0) 140 (94.0)
EGFR FISH 11 (7.0) 145 (93.0) 0.4
EGFR FISH 20 (9.5) 190 (90.5)
MET FISH 3 (6.7) 42 (93.3) 0.72
MET FISH 30 (8.2) 336 (91.8)
HER2 FISH 1 (1.7) 57 (98.3) 0.1
HER2 FISH 31 (8.5) 336 (91.5)
EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization;
MET, mesenchymal-epithelial transition factor; HER2, human epidermal growth factor
receptor 2.
FIGURE 2. Survival in non-small cell lung cancer according
to p95HER2. In the study population, p95HER2 patients
had shorter survival (41.3months, n  398) than p95HER
patients (not reached, n  33). The difference was not sta-
tistically significant (p  0.21).
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(18.1%) coamplified also for EGFR gene. Median survival
was 36.0 months in HER2 FISH positive and 42.0 months
in HER2 FISH negative (p  0.48, Figure 3A). No differ-
ence in survival was detected even when the observation
was confined to patients with HER2 gene amplification
(38.0 months in HER2 amplified versus 41.3 in HER2
nonamplified, p  0.47, Figure 3B). No difference in
survival was observed in any subgroup of patients, includ-
ing the small subgroup of MET FISH positive, as illus-
trated in Figure 4.
DISCUSSION
In this study, we investigated whether p95HER2 could
be implicated in primary resistance to HER2-mab therapy in
NSCLC and observed that this event occur in less than 10%
of patients, mainly in absence of HER2 amplification or
mutation and has no prognostic effect.
The activity of HER2-mab, including trastuzumab and
pertuzumab, has been evaluated in NSCLC in phase II trials
with disappointing results.10–15 Although it is possible that
the lack of patient selection was responsible for clinical trial
failures, it is not possible to exclude that additional biological
markers could be responsible for drug resistance even in the
presence of the target. In the trial conducted by Gatzmeier et
al.,10 where only a small proportion of patients displayed
HER2 gene amplification, the small subset of individuals with
strong HER2 expression (3) and HER2 amplified had a
prolonged response to trastuzumab therapy. Nevertheless, it
is unknown whether this effect was related to trastuzumab or
to chemotherapy, considering that HER2 amplification is
frequently associated with EGFR gene amplification and
mutation, a biological event increasing sensitivity to anti-
EGFR agents as well as to chemotherapy.3,6 In the current
study, where all patients were previously investigated for
EGFR by FISH, a significant association between HER2 and
EGFR GCN was observed, confirming our previous observa-
tion.6 In the pertuzumab trial, among the 43 treated patients,
no response was observed. Moreover, no association of
HER2 expression levels, evaluated by IHC, and progression-
free survival (PFS) was detected, indicating a modest effect
of the drug, at least when used as single agent.11 Other small
phase II trials investigating the efficacy of trastuzumab to-
gether with chemotherapy reported a response rate compara-
ble to that achievable with a standard chemotherapy alone,
suggesting that the drug is ineffective in most of NSCLC.12–15
TABLE 3. Survival in p95HER2 Positive and Negative Patients According to Clinical and Biological Characteristics
Characteristic p95HER2, N (mo) p95HER2, N (mo) p Hazard Ratio
All 33 (NR) 398 (41.3) 0.21 1.41 (1.09–1.83)
Female 2 (51.0) 68 (35.0) 0.41 1.52 (0.03–86)
Male 31 (NR) 330 (44.0) 0.27 1.35 (1.02–1.79)
Never-smokers 0 (—) 40 (61.0) — —
Smokers (former  current) 33 (NR) 341 (41.3) 0.21 1.42 (1.09–1.85)
Adenocarcinoma 7 (17.5) 210 (38.5) 0.22 0.48 (0.11–1.98)
Other histology 26 (NR) 188 (44.0) 0.1 1.82 (1.27–2.6)
Grade I–II 19 (NR) 249 (46.0) 0.21 1.5 (0.95–2.4)
Grade III 12 (35.0) 134 (32.0) 0.42 0.96 (0.46–2)
Stage I–II 24 (NR) 237 (NR) 0.44 1.0 (0.69–1.45)
Stage III–IV 9 (8.4) 140 (18.5) 0.44 2.22 (0.86–5.78)
EGFR FISH 11 (NR) 145 (38.0) 0.28 1.44 (0.66–3.1)
EGFR FISH 20 (NR) 190 (45.0) 0.38 1.33 (0.86–2)
MET FISH 3 (27.5) 42 (23.3) 0.45 1.25 (0.05–29.7)
MET FISH 30 (NR) 336 (45.0) 0.24 1.46 (1.09–1.94)
HER2 FISH 1 (35.0) 57 (36.5) 0.48 —
HER2 FISH 31 (50.0) 336 (44.0) 0.36 1.21 (0.92–1.6)
EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; MET, mesenchymal-epithelial transition factor; HER2, human epidermal growth factor receptor
2; NR, not reached.
TABLE 4. HER2 GCN and Association with Clinical and
Biological Characteristics
Characteristic
HER2 FISH,
N (%)
HER2 FISH,
N (%) p
All 60 (13.7) 379 (86.3)
Female 9 (12.5) 63 (87.5) 0.75
Male 51 (13.9) 316 (86.1)
Never-smokers 6 (15.8) 32 (84.2) 0.74
Smokers (former  current) 53 (13.8) 330 (86.2)
Adenocarcinoma 36 (16.5) 183 (83.5) 0.09
Other histology 24 (10.9) 196 (89.1)
Grade I–II 38 (14.0) 234 (86.0) 0.71
Grade III 19 (12.7) 131 (87.3)
Stage I–II 38 (14.6) 223 (85.4) 0.62
Stage III–IV 20 (12.8) 136 (87.2)
EGFR FISH 38 (23.9) 121 (76.1) 0.00004
EGFR FISH 18 (8.5) 194 (91.5)
MET FISH 13 (28.3) 33 (71.7) 0.005
MET FISH 47 (12.6) 327 (87.4)
EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization;
MET, mesenchymal-epithelial transition factor; HER2, human epidermal growth factor
receptor 2; GCN, gene copy number.
Cappuzzo et al. Journal of Thoracic Oncology • Volume 7, Number 3, March 2012
Copyright © 2012 by the International Association for the Study of Lung Cancer524
Overall, these data indicated that monoclonal antibodies
against HER2 are not effective in the majority of NSCLC,
with a potential but no proven efficacy in presence of HER2
amplification.
HER2 activating mutations are rare events in NSCLC,
occurring in approximately 2% of cases and mainly in fe-
males and never-smokers.28 During the last years, preclinical
investigations revealed that NSCLC cell lines harboring
HER2 mutations are sensitive to trastuzumab therapy. Wang
et al.29 reported that anti-HER2 agents including trastuzumab
inhibited H1718 lung cancer cells containing the exon 20
HER2 mutation. Moreover, our group reported a case of
pretreated NSCLC patient with HER2 mutation dramatically
responding to the combination of trastuzumab and pacli-
taxel.16 These data suggested that anti-HER2 therapies could
be effective in HER2-mutant NSCLC, and the low incidence
of HER2 mutations in unselected NSCLC justify why no sign
of efficacy with anti-HER2 monoclonal antibodies was de-
tected in clinical trials. Spanish investigators reported that
HER2 truncation (p95HER2) frequently occurs in breast
cancer with HER2 amplification and such event is responsible
for trastuzumab failure in approximately 10% of breast can-
cer patients.20 In our study, HER2 truncation only occurred in
less than 10% of NSCLC, predominantly in HER2 wild-type
and nonamplified. Therefore, the incidence of HER2 trunca-
tion in NSCLC is too low for explaining the lack of sensi-
tivity to trastuzumab observed in clinical trials.
In breast cancer, presence of p95HER2 predicts worse
prognosis in HER2 patients.18,30,31 Our analysis, the first
conducted in NSCLC and analyzing a large cohort of pa-
tients, revealed a modest and no statistically significant dif-
ference in survival between individuals with or without
HER2 truncation, demonstrating that such event plays no
prognostic role in surgically resected NSCLC.
In the second part of our study, the attention was
focused on the prognostic role of HER2 GCN. A recent
meta-analysis, including 974 patients evaluated by FISH,
showed that HER2 GCN was not a prognostic factor in lung
cancer.7 Nevertheless, the meta-analysis included seven stud-
ies using different scoring systems and reporting discordant
results. Herein, we report data from a large cohort of NSCLC
surgically treated before adjuvant chemotherapy became a
standard approach. These data, obtained without a potential
FIGURE 3. HER2 gene copy number and patient survival. The panel shows overall survival in HER2 FISH positive and HER2
negative patients (defined using the Colorado score). A, Patients with increase of HER2 gene copy number (HER2 FISH, n 
60) had shorter survival than individuals with no increased HER2 gene copy number (HER2 FISH, n  379). Median survival
was 36.0 months in HER2 FISH and 42.0 months in HER2 FISH. This difference was not statistically significant (p  0.48).
B, The small subgroup of patients with HER2 gene amplification (HER2 GA, n  22) had a median survival of 38.0 months
versus 41.3 months in the HER2 nonamplified group (HER2 no GA, n  417). The difference was not statistically significant
(p  0.47).
FIGURE 4. Survival according to HER2 and MET gene am-
plification. No difference in survival was detected when HER2
gene copy number assessment was evaluated in the context
of MET amplification, defined as a mean MET gene copy
number 5. The subgroup of patients with MET FISH posi-
tive and HER2 gene amplification (MET FISH/HER2 GA, n 
10) had a median survival of 36 months versus 20.5 months
in MET FISH positive and HER2 nonamplified (MET FISH/
HER2 no GA, n  36). The difference was not statistically
significant (p  0.26).
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confounding effect of chemotherapy, confirmed that in-
creased HER2 GCN is not prognostic in resected NSCLC.
Importantly, no difference in survival was detected even
when the analyses were confined to patients with HER2 gene
amplification or in the context of increased MET GCN.
An intriguing result of our study was the significant
association between EGFR, HER2, and MET GCN. Our data
provide further evidence that NSCLC does not depend
uniquely on HER2 signaling even in presence of HER2
amplification or copy number gain. Studies on NSCLC and
breast cancer cell lines shown complex signaling crosstalk
between receptor tyrosine kinases and downstream mole-
cules, in particular EGFR, HER2, HER3, c-Met, and
AKT.32,33 EGFR and MET have been shown to crosstalk
physically and functionally. EGFR has the ability to act as a
scaffolding protein to link MET and c-Src.34 MET is com-
monly expressed in HER2 breast cancers and directly
implicated in the development of trastuzumab resistance,
through sustained HER3-PI3K-AKT signaling. The concept
of targeting MET pathway as a strategy to circumvent resis-
tance to anti-EGFR or HER2 agents is very attractive, but it
has to be prospectively assessed in clinical trials.32,35
In conclusion, HER2 truncation and increased GCN are
not prognostic in resected NSCLC. Although p95HER2 is
present in a small fraction of NSCLC, mainly in tumors with
HER2 wild-type or nonamplified, it is unlikely that this event
is responsible for the lack of efficacy of HER2-mab therapies
observed in clinical trials. The strong association of HER2
GCN with EGFR and MET GCN support the association of
anti-HER2 agents with other targeted drugs in selected
NSCLC.
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